Clinical Trial Update: A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating IBI3033 for moderate-to-severe atopic dermatitis; recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• IBI3033

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Atopic Dermatitis | Phase 1 | Status: NOT_YET_RECRUITING